Acute Ocular Pain Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies – Aldeyra, Sylentis, Ocular Therapeutix, Kala Pharma

June 05 07:08 2023
Acute Ocular Pain Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies - Aldeyra, Sylentis, Ocular Therapeutix, Kala Pharma
Delveinsight Business Research LLP
As per DelveInsight, the Acute Ocular Pain Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and the expected entry of emerging therapies in the market. Several companies are working robustly on many new therapies, such as Oculis SA (OCS-01), Surface Ophthalmics (SURF), Formosa Pharmaceuticals (APP13007), Salvat Laboratories (SVT-15473), Visiox Pharma (SDN-037), EyePoint Pharmaceuticals (DEXYCU), and several others.

DelveInsight’s “Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Ocular Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Acute Ocular Pain drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Ocular Pain treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Acute Ocular Pain: An Overview

Eye pain is a myriad of symptoms, ranging from sharp pain in the eye to mild discomfort or itching in the eyes. As the spectrum of symptom presentation varies with eye pain, the cause of these pains may vary from very simple refractive errors to potentially sight-threatening disorders like glaucoma and uveitis.

Eye pain or ocular pain can be differentiated into chronic ocular pain and acute ocular pain. A feeling of discomfort or pain in the eye can be caused by a problem in the eye itself. It can also be caused by a problem involving any of the structures around the eye or referred pain from tissues with similar innervation as ocular tissues.

Eye pain that occurs deeper within the eye may feel aching, gritty, stabbing, or throbbing. This kind of eye pain may require more in-depth treatment. Eye pain accompanied by vision loss may be a symptom of an emergency medical issue.

Acute Ocular Pain Market Key Facts

  • The market size in the EU5 is expected to increase to USD 153.6 million by 2032 due to the rising awareness of the disease and launch of the emerging therapies.

  • Dextenza, Inveltys, and Lotemax SM—already approved in the US market—are expected to enter the European and Japanese markets in 2023, 2023, and 2024, respectively.

  • The United States is expected to capture the largest market share of Acute Ocular Pain by 2032. 

  • In 2020 the US accounted for 4,038,628 AOP cases, which is anticipated to increase by 2032.

  • In 2020, the EU5 countries accounted for 4,527,206 cases, which is seen to increase by 2032.

  • Among EU5 countries, Germany had the highest number of cases of Acute Ocular Pain (AOP), which were 1,109,517 cases in 2020. As per DelveInsight’s estimates, this count will increase throughout the study period.

  • Japan, in 2020, accounted for 1,315,445 cases of AOP.

Acute Ocular Pain Market

Acute Ocular Pain Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Ocular Pain pipeline therapies. It also thoroughly assesses the Acute Ocular Pain market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Acute Ocular Pain drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Acute Ocular Pain Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Acute Ocular Pain epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Ocular Pain epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Acute Ocular Pain Epidemiology, Segmented as –

  • Number of Cases of Several Eye Disorders in the 7MM [2019–2032]

  • Number of Cases of Acute Ocular Pain in Major Eye Disorders in the 7MM [2019–2032]

Acute Ocular Pain Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Ocular Pain market or expected to be launched during the study period. The analysis covers the Acute Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Acute Ocular Pain drugs based on their sale and market share.

The report also covers the Acute Ocular Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Ocular Pain companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Acute Ocular Pain Market Will Evolve and Grow by 2032 @

Acute Ocular Pain Companies Actively Working in the Therapeutics Market Include

  • Formosa Pharmaceuticals

  • Sun Pharmaceutical

  • Ocular Therapeutix

  • Kala Pharmaceuticals

  • Bausch & Lomb

  • Aldeyra Therapeutics

  • Surface Ophthalmics

  • Sylentis

  • Kala Pharmaceuticals

And Many Others

Emerging and Marketed Acute Ocular Pain Therapies Covered in the Report Include:

  • APP13007: Formosa Pharmaceuticals

  • BromSite (bromfenac ophthalmic solution): Sun Pharmaceutical

  • Dextenza (dexamethasone ophthalmic insert): Ocular Therapeutix

  • Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals

  • Lotemax SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb

  • Prolensa (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb

  • Reproxalap: Aldeyra Therapeutics

  • SURF-201: Surface Ophthalmics

  • Tivanisiran (SYL1001): Sylentis

  • Dextenza (dexamethasone ophthalmic insert): Ocular Therapeutix

  • Inveltys (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Acute Ocular Pain Competitive Intelligence Analysis

4. Acute Ocular Pain Market Overview at a Glance

5. Acute Ocular Pain Disease Background and Overview

6. Acute Ocular Pain Patient Journey

7. Acute Ocular Pain Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Acute Ocular Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Ocular Pain Unmet Needs

10. Key Endpoints of Acute Ocular Pain Treatment

11. Acute Ocular Pain Marketed Therapies

12. Acute Ocular Pain Emerging Drugs and Latest Therapeutic Advances

13. Acute Ocular Pain Seven Major Market Analysis

14. Attribute Analysis

15. Acute Ocular Pain Market Outlook (In US, EU5, and Japan)

16. Acute Ocular Pain Companies Active in the Market

17. Acute Ocular Pain Access and Reimbursement Overview

18. KOL Views on the Acute Ocular Pain Market

19. Acute Ocular Pain Market Drivers

20. Acute Ocular Pain Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Fetal Monitoring Devices Market

The Global Fetal Monitoring Devices Market was valued at USD 3.16 Billion in 2021, growing at a CAGR of 6.92% during the forecast period from 2023 to 2028; it is expected to reach USD 4.72 Billion by 2028. The increase in demand for Fetal Monitoring Devices is primarily attributed to the increased need for monitoring fetuses for various birth defects and the prevalence of preterm births, and post-term pregnancy, the development of technologically advanced fetal monitors, the growing adoption of minimally invasive procedures, and increase in government and non-government initiatives for maternal and fetal health across the world.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States